-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The industry said that in the context of centralized procurement, pharmaceutical companies will move in a direction that suits them
.
Among them, the acquisition or sale of pharmaceutical companies will become more frequent
.
"Behind this is either the company's strategic adjustments, focusing on core business; or the company eliminating competitors and increasing market share; or realizing commercial value in advance
.
" It is understood that recently, news of pharmaceutical companies' sales continues
.
For example, Dongyang Sunshine announced on the evening of November 11 that it intends to sell 226 million domestic shares of Dongyang Pharmaceutical to Guangyao Pharmaceutical and 226 million H-share "fully-tradable" shares of Dongyang Pharmaceutical to Hong Kong Dongyang Pharmaceutical, a wholly-owned subsidiary of Guangyao
.
The above-mentioned shares to be transferred total 452 million shares, accounting for approximately 51.
41% of the total share capital of Dongyang Sun Pharmaceutical
.
After friendly negotiation, it is determined that the transaction price of Dongyang Sunshine Pharmaceutical Co.
, Ltd.
in this transaction is 3.
723 billion yuan
.
Dongyangguang said that through this transaction, the company will no longer be engaged in the production and sales of pharmaceutical-related products; the company will actively expand new businesses in the fields of new energy such as variable frequency energy storage and new energy vehicles
.
On November 4, Jinghua Pharmaceutical issued an announcement, announcing that it had recently completed the sale of the equity of its subsidiary Wannianchang Pharmaceutical.
The transferee of the equity was Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of 69.
39 million yuan
.
Another example is Tianyao's recent announcement that Fosun Pharma intends to transfer its 25 shares of Tianjin Pharmaceutical Group, the controlling shareholder of the company, to Jinyao Group, the indirect controlling shareholder of the company, at a price of 1.
433 billion yuan
.
After the equity transfer is completed, Fosun Pharma will no longer hold the equity of the Pharmaceutical Group, and Jinyao Group will eventually hold 99.
0014% of the equity of the Pharmaceutical Group
.
Huayuan Biological also announced recently that the company intends to acquire 100% equity of Huayuan Pharmaceutical for 1.
07 billion yuan in cash
.
Guangzhou Xiangxue Pharmaceutical Co.
, Ltd.
also recently issued a "Announcement on the Transfer of Subsidiary Equity", which will transfer 100% of the equity of Guangdong Zhaoyang Biotechnology Co.
, Ltd.
, a wholly-owned subsidiary of the company after the division.
.
Recently, Asia-Pacific Pharmaceuticals also issued the "Announcement on the Progress of the Judicial Auction of Some Shares of the Controlling Shareholders and Those Acting in Concert".
34.
5 million shares
.
Analysts pointed out that in recent years, with the continuous advancement of the medical reform policy, the pharmaceutical industry knockout competitions are constantly being staged
.
Among them, pharmaceutical companies can obtain new performance growth or consolidate their position in the industry through actions such as sales or acquisitions
.
For SMEs, acquisitions and mergers can also be another way out for their own development
.
For example, Xiangxue Pharmaceutical said that for this transfer, the integration and optimization of asset structure and resource allocation, improved asset liquidity and utilization efficiency, are conducive to the company's focus on the development of its main business and enhance its core competitiveness
.
For transactions in the pharmaceutical industry, not only domestic pharmaceutical companies, but also multinational companies will sell entire business units or drugs in order to revitalize their assets
.
For example, Novartis announced that it had signed a $20.
7 billion transaction agreement with Roche to sell Roche’s shares acquired since 20 years ago
.
With the changes and deepening of policies, the “extracting the essence and removing the dross” approach has become an important transformation model for enterprises.
“Only by optimizing the allocation of resources and focusing on core business can operating risks be minimized
.
” Some industry insiders said
.
.
Among them, the acquisition or sale of pharmaceutical companies will become more frequent
.
"Behind this is either the company's strategic adjustments, focusing on core business; or the company eliminating competitors and increasing market share; or realizing commercial value in advance
.
" It is understood that recently, news of pharmaceutical companies' sales continues
.
For example, Dongyang Sunshine announced on the evening of November 11 that it intends to sell 226 million domestic shares of Dongyang Pharmaceutical to Guangyao Pharmaceutical and 226 million H-share "fully-tradable" shares of Dongyang Pharmaceutical to Hong Kong Dongyang Pharmaceutical, a wholly-owned subsidiary of Guangyao
.
The above-mentioned shares to be transferred total 452 million shares, accounting for approximately 51.
41% of the total share capital of Dongyang Sun Pharmaceutical
.
After friendly negotiation, it is determined that the transaction price of Dongyang Sunshine Pharmaceutical Co.
, Ltd.
in this transaction is 3.
723 billion yuan
.
Dongyangguang said that through this transaction, the company will no longer be engaged in the production and sales of pharmaceutical-related products; the company will actively expand new businesses in the fields of new energy such as variable frequency energy storage and new energy vehicles
.
On November 4, Jinghua Pharmaceutical issued an announcement, announcing that it had recently completed the sale of the equity of its subsidiary Wannianchang Pharmaceutical.
The transferee of the equity was Jiangsu Qichen New Materials Co.
, Ltd.
, with a transaction amount of 69.
39 million yuan
.
Another example is Tianyao's recent announcement that Fosun Pharma intends to transfer its 25 shares of Tianjin Pharmaceutical Group, the controlling shareholder of the company, to Jinyao Group, the indirect controlling shareholder of the company, at a price of 1.
433 billion yuan
.
After the equity transfer is completed, Fosun Pharma will no longer hold the equity of the Pharmaceutical Group, and Jinyao Group will eventually hold 99.
0014% of the equity of the Pharmaceutical Group
.
Huayuan Biological also announced recently that the company intends to acquire 100% equity of Huayuan Pharmaceutical for 1.
07 billion yuan in cash
.
Guangzhou Xiangxue Pharmaceutical Co.
, Ltd.
also recently issued a "Announcement on the Transfer of Subsidiary Equity", which will transfer 100% of the equity of Guangdong Zhaoyang Biotechnology Co.
, Ltd.
, a wholly-owned subsidiary of the company after the division.
.
Recently, Asia-Pacific Pharmaceuticals also issued the "Announcement on the Progress of the Judicial Auction of Some Shares of the Controlling Shareholders and Those Acting in Concert".
34.
5 million shares
.
Analysts pointed out that in recent years, with the continuous advancement of the medical reform policy, the pharmaceutical industry knockout competitions are constantly being staged
.
Among them, pharmaceutical companies can obtain new performance growth or consolidate their position in the industry through actions such as sales or acquisitions
.
For SMEs, acquisitions and mergers can also be another way out for their own development
.
For example, Xiangxue Pharmaceutical said that for this transfer, the integration and optimization of asset structure and resource allocation, improved asset liquidity and utilization efficiency, are conducive to the company's focus on the development of its main business and enhance its core competitiveness
.
For transactions in the pharmaceutical industry, not only domestic pharmaceutical companies, but also multinational companies will sell entire business units or drugs in order to revitalize their assets
.
For example, Novartis announced that it had signed a $20.
7 billion transaction agreement with Roche to sell Roche’s shares acquired since 20 years ago
.
With the changes and deepening of policies, the “extracting the essence and removing the dross” approach has become an important transformation model for enterprises.
“Only by optimizing the allocation of resources and focusing on core business can operating risks be minimized
.
” Some industry insiders said
.
